Previous close | 8.50 |
Open | 8.45 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 155.00 |
Expiry date | 2024-11-15 |
Day's range | 8.00 - 8.85 |
Contract range | N/A |
Volume | |
Open interest | 456 |
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024). AbbVie's ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein), which are over-expressed across various tumor types. By utilizing these biomarkers as targets, ADCs are